Comparison of oral aspirin versus topical applied methyl salicylate for platelet inhibition

Annals of Pharmacotherapy

Volumn 42, Issue 10, 2008, Pages 1396-1401

  Tanen, David A ^a   Danish, D Christopher ^a   Reardon, Jacqueline M ^a   Chisholm, Christopher B ^a   Matteucci, Michael J ^a   Riffenburgh, Robert H ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

Aspirin; Methyl salicylate; Platelets; Thromboxane

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; SAFEWAY CHILDREN ASPIRIN; SAFEWAY MUSCLE RUB; SALICYLIC ACID METHYL ESTER; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGGREGOMETER; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; ENZYME IMMUNOASSAY; HEART INFARCTION; HUMAN; HUMAN EXPERIMENT; MALE; MEASUREMENT; METABOLITE; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; THROMBOCYTE AGGREGATION INHIBITION; VOLUNTEER; WILCOXON SIGNED RANKS TEST;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ASPIRIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EPINEPHRINE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; SALICYLATES; STATISTICS, NONPARAMETRIC; THROMBOXANE B2; TIME FACTORS;

EID: 52949088320     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L128     Document Type: Article

References (17)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;8607:349-60.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
3. Patrono C. Drug therapy: aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-94.
4. Keimowitz RM, Pulvermacher G, Mayo G, Fitzgerald DJ. Transdermal modification of platelet function. A dermal aspirin preparation selectively inhibits platelet cyclooxygenase and preserves prostacyclin biosynthesis. Circulation 1993;88:556-61.
5. McAdam B, Keimowitz RM, Maher M, Fitzgerald DJ. Transdermal modification of platelet function: an aspirin patch system results in marked suppression of platelet cyclooxygenase. J Pharmacol Exp Ther 1996;277:559-64.
6. Morra P, Bartle WR, Walker SE, et al. Serum concentrations of salicylic acid following topically applied salicylate derivatives. Ann Pharmacother 1996;30:935-40.
7. Collins AJ, Notarianni LJ, Ring EFJ, Seed MP. Some observations on the pharmacology of 'deep-heat,' a topical rubifacient. Ann Rheum Dis 1984;43:411-5.
8. Born GVR. Quantitative investigations into the aggregation of blood products. J Physiol 1962;162:67-8.
9. Kanto J, Klossner J, Yrjana T. Bioavailability of rectal aspirin in neurosurgical patients. Acta Anaesthesiol Scand 1981;25:25-6.
10. Dalvi SS, Gupta KC, Pohujani SM, et al. Bioavailability of aspirin after oral and rectal administration in volunteers and patients with fever. J Postgrad Med 1985;3:192-5.
11. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004;126(suppl):513S-48S.
12. Skrakosch E. Studies on ointment: II. Ointments containing salicylic acid. Arch Derm Syph 1943;47:16-26.
13. Skrakosch E. Studies on ointments: IV. Local action of salicylic acid plus sulfur from various ointment bases. Arch Derm Syph 1943;48:384-92.
14. Brubacher JR, Hoffman RS. Salicylism from topical salicylates: review of the literature. J Toxicol Clin Toxicol 1996;34:431-6.
15. 2 production during aspirin treatment; dependence on the dose of the aggregating agent. Thromb Res 1985;37:337-42.
16. Rotilio D, Joseph D, Hatmi M, Varfaftig BB. Structural requirements for preventing the aspirin- and the arachidonate-induced inactivation of platelet cyclo-oxygenase: additional evidence for distinct enzymatic sites. Eur J Pharmacol 1984;97:197-208.
17. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-72.